To determine whether targeting AKT and disrupting the interaction between EGFR and pAKTSer473 could enhance gefitinib efficacy in lung cancer cells with mt-BRG1 and wt-EGFR status, H358-BRG1-KO and parental A549 (mt-BRG1) cells were treated with gefitinib alone (2 μM or 10 μM GEF), MK2206 (0.25 μM) alone, or the combination of both drugs. Here, SMARCA4 is linked to lung carcinoma.